News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proteonomix, Inc. (PROT) Announces Termination of Contract with the University of Miami



4/11/2012 10:18:01 AM

HAWTHORNE, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced the termination of the Research Agreement and Phase 1 clinical trial with the University of Miami. This agreement is related to the Company’s compound UMK-121 for End Stage Liver Disease (ESLD) and was entered into on November 15, 2011.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES